LivaNova PLC (LIVN) shares surged 12.12% in pre-market trading on Wednesday following the release of better-than-expected first-quarter 2025 results, raised full-year guidance, and positive clinical data for its sleep apnea treatment.

The medical technology company reported Q1 revenue of $316.9 million, surpassing the IBES estimate of $302.3 million. Adjusted earnings per share came in at $0.88, significantly beating the expected $0.76. LivaNova's strong performance was driven by high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion.

In light of the robust results, LivaNova raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%. The company also updated its adjusted diluted earnings per share range to $3.60 to $3.70. Adding to the positive sentiment, LivaNova announced encouraging 12-month data from its OSPREY clinical study for moderate to severe obstructive sleep apnea. The study demonstrated strong response and durability of therapy, with an overall responder rate of 65% and a 68% reduction in both the median Apnea-Hypopnea Index and Oxygen Desaturation Index. These results, coupled with the company's recent premarket approval submission to the FDA for its aura6000 System, suggest potential future growth opportunities in the sleep apnea market for LivaNova.